MannKind-Mexican Trademarks
Apr 8, 2018 23:12:15 GMT -5
edvarney, sportsrancho, and 9 more like this
Post by mango on Apr 8, 2018 23:12:15 GMT -5
Inspired by the burrito chipotle from earlier I figured a thread was in order.
“Diabetes is a public health emergency in Mexico.”
—Pablo Kuri, Undersecretary for Prevention at the Mexican Health Ministry
In 2016, Mexico declared diabetes a national health emergency. T2D is the leading cause of death in Mexico. Additionally, diabetes-related complications cause half of all deaths in Mexico between the ages of 35-74. Mexico’s health emergency is further exacerbated by the country’s splintered healthcare system. It is estimated that at least half of those with T2D in Mexico go undiagnosed. Majority are well into the disease process when an initial diagnosis is made, making early treatment intervention a rare occurrence.
The constant state of energy imbalance among those that go undiagnosed until they are in the advanced stages of disease will have significant complications to realize all at once, and treatment of the person with diabetes should ideally be restoring glucose homeostasis, so Afrezza plus a CGM plus One Drop addresses the glucose imbalance and addresses some of the socio-economic challenges that many face in Mexico. Progression of chronic related conditions would began to diminish upon restoring energy homeostasis.
This is simple and not complicated. The treatment is a simple package that requires very little of the person needing it. Afrezza is simple to use and understand and poses very little concern of hypoglycemia as long as the person eats before using it. A CGM can easily be understood by both children and the elderly, tackling totally opposite age populations while also seeing that early and effective disease intervention is employed by encouraging screening of children. One Drop app provides a connection to a proactive and helpful community plus has invaluable information and services that could be of potential benefit of the person with T2D. There is an added benefit with One Drop and that is its effectiveness is backed by FDA approved clinical trial and the ongoing trials with Afrezza will only strengthen its therapeutic potential.
Majority of the citizens of Mexico have health insurance, and it appears that the health regulatory oversight created for this emergency is more interested in patient outcomes and long-term value of the treatment versus a Consensus Statement from an organization run by vast bureaucracies.
“We need to re-conceptualize the way that we address health problems because our main challenge is chronic diseases,” says Dr Rafael Lozano, director of the Centre for Health Systems Research at Mexico’s National Institute of Public Health.
Lozano says that the mindset of the typical Mexican health-care provider is still lodged in the 20th century: they are prepared to deal with infections or acute episodes, but do not think in terms of the need for follow-up and management of chronic disease over time.
Status: Active (2017-11-07)
Registration Number
1817343
Date of the registration
2017-11-07
Serial number of the application
0119851932637
Date of filing of the application
2017-08-15
Expected expiration date of the registration/renewal
2027-08-15
International Classification of the Figurative Elements of Marks (Vienna Classification)
01.13.01, 01.13.15, 02.01.23, 02.01.30, 24.17.01, 24.17.02.
Indication relating to the nature or kind of mark
Trade mark
Name and address of the applicant
MANNKIND CORPORATION
RUSSELL RANCH ROAD NUM. EXT. 30930 NUM. INT. SUITE 301
WESTLAKE VILLAGE, CA., ESTADOS UNIDOS DE AMERICA (91362)
Name and address of the representative
ANTONIO BELAUNZARAN MARTINEZ
PEDRO LUIS OGAZON NUM. EXT. 17, SAN ANGEL
ALVARO OBREGON, CIUDAD DE MEXICO (01000)
The International Classification of Goods and Services for the Purposes of the Registration of Marks (Nice Classification) and the list of goods and services classified according thereto
PRODUCTOS FARMACEUTICOS, INCLUYENDO PREPARACIONES FARMACEUTICAS PARA EL TRATAMIENTO DE ALERGIAS, LA ENFERMEDAD DE ALZHEIMER, EL ASMA, ENFERMEDADES Y TRASTORNOS AUTOINMUNES, CANCER, ENFERMEDADES Y TRASTORNOS CARDIOVASCULARES, ENFERMEDADES Y TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL Y NEUROLOGICOS, DIABETES, ENFERMEDADES Y TRASTORNOS ENDOCRINOS, DISFUNCION Y DESORDENES ERECTIL Y SEXUALES, ENFERMEDADES Y TRASTORNOS GASTROINTESTINALES, ENFERMEDADES Y TRASTORNOS GINECOLOGICOS Y DE FERTILIDAD, ENFERMEDADES Y DESORDENES HEMOLITICOS, ENFERMEDADES Y TRASTORNOS HORMONALES, HIPERTENSION, ENFERMEDADES INFECCIOSAS, ENFERMEDADES Y TRASTORNOS INMUNOLOGICAS, ENFERMEDADES Y TRASTORNOS BACTERIANAS, ENFERMEDADES Y TRASTORNOS VIRALES Y ENFERMEDADES Y TRASTORNOS POR HONGOS, INFLAMACION Y ENFERMEDADES Y TRASTORNOS INFLAMATORIOS, ENFERMEDADES Y TRASTORNOS METABOLICOS, MIGRAÑAS, ENFERMEDADES Y TRASTORNOS MUSCULO ESQUELETICOS, ENFERMEDADES Y TRASTORNOS NEOPLASICOS, OBESIDAD, ENFERMEDADES Y TRASTORNOS OFTALMOLOGICOS Y OCULARES, OSTEOPOROSIS, DOLOR, ENFERMEDAD DE PARKINSON, ENFERMEDADES Y TRASTORNOS PSIQUIATRICOS, ENFERMEDADES Y TRASTORNOS RESPIRATORIOS, TABAQUISMOS Y ADICCIONES A SUSTANCIAS Y ENFERMEDADES Y TRASTORNOS RELACIONADOS, ACCIDENTES CEREBROVASCULARES, TRASTORNOS UROLOGICOS, CONTROL DEL PESO Y APETITO.
...translating…
PHARMACEUTICAL PRODUCTS, INCLUDING PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF ALLERGIES, ALZHEIMER'S DISEASE, ASTHMA, AUTOIMMUNE DISEASES AND DISORDERS, CANCER, CARDIOVASCULAR DISEASES AND DISORDERS, NEUROLOGICAL AND CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS, ENDOCRINE DISEASES AND DISORDERS, ERECTILE DYSFUNCTION AND SEXUAL DISORDERS, GASTROINTESTINAL DISEASES AND DISORDERS, GYNECOLOGICAL AND FERTILITY DISEASES AND DISORDERS, HEMOLYTIC DISEASES AND DISORDERS, HORMONAL DISEASES AND DISORDERS, HYPERTENSION, INFECTIOUS DISEASES, IMMUNOLOGICAL DISEASES AND DISORDERS, BACTERIAL DISEASES AND DISORDERS, VIRAL DISEASES AND DISORDERS AND FUNGAL DISEASES AND DISORDERS, INFLAMMATION AND INFLAMMATORY DISEASES AND DISORDERS, METABOLIC DISEASES AND DISORDERS, MIGRAINES, MUSCULOSKELETAL DISEASES AND DISORDERS, NEOPLASTIC DISEASES AND DISORDERS, OBESITY, OPHTHALMOLOGICAL AND EYE DISEASES AND DISORDERS, OSTEOPOROSIS, PAIN, PARKINSON DISEASE, PSYCHIATRIC DISEASES AND DISORDERS, RESPIRATORY DISEASES AND DISORDERS, TOBACCO AND ADDICTIONS TO SUBSTANCES AND RELATED DISEASES DISORDERS, CEREBROVASCULAR ACCIDENTS, UROLOGICAL DISORDERS, WEIGHT CONTROL AND APPETITE.
www.wipo.int/branddb/en/showData.jsp?ID=MXTM.0119851932637
AFRESA
Status: Pending (2018-03-12)
Serial number of the application
0119852021378
Date of filing of the application
2018-03-12
Reproduction of the mark where the mark is represented in standard characters
AFRESA
Indication relating to the nature or kind of mark
Trade mark
Name and address of the applicant
MANNKIND CORPORATION
RUSSELL RANCH ROAD NUM. EXT. 30930 NUM. INT. SUITE 301
WESTLAKE VILLAGE, CA., ESTADOS UNIDOS DE AMERICA (91362)
Name and address of the representative
ANTONIO BELAUNZARAN MARTINEZ
PEDRO LUIS OGAZON NUM. EXT. 17, SAN ANGEL
ALVARO OBREGON, CIUDAD DE MEXICO (01000)
The International Classification of Goods and Services for the Purposes of the Registration of Marks (Nice Classification) and the list of goods and services classified according thereto
PREPARACIONES FARMACEUTICAS.
…translating…
PHARMACEUTICAL PREPARATIONS.
www.wipo.int/branddb/en/showData.jsp?ID=MXTM.0119852021378
“Diabetes is a public health emergency in Mexico.”
—Pablo Kuri, Undersecretary for Prevention at the Mexican Health Ministry
In 2016, Mexico declared diabetes a national health emergency. T2D is the leading cause of death in Mexico. Additionally, diabetes-related complications cause half of all deaths in Mexico between the ages of 35-74. Mexico’s health emergency is further exacerbated by the country’s splintered healthcare system. It is estimated that at least half of those with T2D in Mexico go undiagnosed. Majority are well into the disease process when an initial diagnosis is made, making early treatment intervention a rare occurrence.
The constant state of energy imbalance among those that go undiagnosed until they are in the advanced stages of disease will have significant complications to realize all at once, and treatment of the person with diabetes should ideally be restoring glucose homeostasis, so Afrezza plus a CGM plus One Drop addresses the glucose imbalance and addresses some of the socio-economic challenges that many face in Mexico. Progression of chronic related conditions would began to diminish upon restoring energy homeostasis.
This is simple and not complicated. The treatment is a simple package that requires very little of the person needing it. Afrezza is simple to use and understand and poses very little concern of hypoglycemia as long as the person eats before using it. A CGM can easily be understood by both children and the elderly, tackling totally opposite age populations while also seeing that early and effective disease intervention is employed by encouraging screening of children. One Drop app provides a connection to a proactive and helpful community plus has invaluable information and services that could be of potential benefit of the person with T2D. There is an added benefit with One Drop and that is its effectiveness is backed by FDA approved clinical trial and the ongoing trials with Afrezza will only strengthen its therapeutic potential.
Majority of the citizens of Mexico have health insurance, and it appears that the health regulatory oversight created for this emergency is more interested in patient outcomes and long-term value of the treatment versus a Consensus Statement from an organization run by vast bureaucracies.
“We need to re-conceptualize the way that we address health problems because our main challenge is chronic diseases,” says Dr Rafael Lozano, director of the Centre for Health Systems Research at Mexico’s National Institute of Public Health.
Lozano says that the mindset of the typical Mexican health-care provider is still lodged in the 20th century: they are prepared to deal with infections or acute episodes, but do not think in terms of the need for follow-up and management of chronic disease over time.
- MannKind currently has 17 active Mexican trademarks and 6 pending Mexican trademarks.
- The trademarks collectively reflect what would be needed if planning to roll out into a new territory.
- The opioid crisis in America creates complex challenges between the US and Mexico. MannKind has much to consider but even more to offer.
- Who would partner with MannKind in Mexico? BIOMM is located in Brazil. It would be realistic to assume BIOMM would like to cover neighboring countries, but whether BIOMM has even considered Mexico remains unknown.
- One specific active MannKind-Mexican trademark that caught my attention was this one here below. The mark is the MannKind symbol in my avatar minus the heart and quote. This trademark was recently filed and registered just late 2017. It appears to cover nearly all known diseases and disorders that affects humans.
Status: Active (2017-11-07)
Registration Number
1817343
Date of the registration
2017-11-07
Serial number of the application
0119851932637
Date of filing of the application
2017-08-15
Expected expiration date of the registration/renewal
2027-08-15
International Classification of the Figurative Elements of Marks (Vienna Classification)
01.13.01, 01.13.15, 02.01.23, 02.01.30, 24.17.01, 24.17.02.
Indication relating to the nature or kind of mark
Trade mark
Name and address of the applicant
MANNKIND CORPORATION
RUSSELL RANCH ROAD NUM. EXT. 30930 NUM. INT. SUITE 301
WESTLAKE VILLAGE, CA., ESTADOS UNIDOS DE AMERICA (91362)
Name and address of the representative
ANTONIO BELAUNZARAN MARTINEZ
PEDRO LUIS OGAZON NUM. EXT. 17, SAN ANGEL
ALVARO OBREGON, CIUDAD DE MEXICO (01000)
The International Classification of Goods and Services for the Purposes of the Registration of Marks (Nice Classification) and the list of goods and services classified according thereto
PRODUCTOS FARMACEUTICOS, INCLUYENDO PREPARACIONES FARMACEUTICAS PARA EL TRATAMIENTO DE ALERGIAS, LA ENFERMEDAD DE ALZHEIMER, EL ASMA, ENFERMEDADES Y TRASTORNOS AUTOINMUNES, CANCER, ENFERMEDADES Y TRASTORNOS CARDIOVASCULARES, ENFERMEDADES Y TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL Y NEUROLOGICOS, DIABETES, ENFERMEDADES Y TRASTORNOS ENDOCRINOS, DISFUNCION Y DESORDENES ERECTIL Y SEXUALES, ENFERMEDADES Y TRASTORNOS GASTROINTESTINALES, ENFERMEDADES Y TRASTORNOS GINECOLOGICOS Y DE FERTILIDAD, ENFERMEDADES Y DESORDENES HEMOLITICOS, ENFERMEDADES Y TRASTORNOS HORMONALES, HIPERTENSION, ENFERMEDADES INFECCIOSAS, ENFERMEDADES Y TRASTORNOS INMUNOLOGICAS, ENFERMEDADES Y TRASTORNOS BACTERIANAS, ENFERMEDADES Y TRASTORNOS VIRALES Y ENFERMEDADES Y TRASTORNOS POR HONGOS, INFLAMACION Y ENFERMEDADES Y TRASTORNOS INFLAMATORIOS, ENFERMEDADES Y TRASTORNOS METABOLICOS, MIGRAÑAS, ENFERMEDADES Y TRASTORNOS MUSCULO ESQUELETICOS, ENFERMEDADES Y TRASTORNOS NEOPLASICOS, OBESIDAD, ENFERMEDADES Y TRASTORNOS OFTALMOLOGICOS Y OCULARES, OSTEOPOROSIS, DOLOR, ENFERMEDAD DE PARKINSON, ENFERMEDADES Y TRASTORNOS PSIQUIATRICOS, ENFERMEDADES Y TRASTORNOS RESPIRATORIOS, TABAQUISMOS Y ADICCIONES A SUSTANCIAS Y ENFERMEDADES Y TRASTORNOS RELACIONADOS, ACCIDENTES CEREBROVASCULARES, TRASTORNOS UROLOGICOS, CONTROL DEL PESO Y APETITO.
...translating…
PHARMACEUTICAL PRODUCTS, INCLUDING PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF ALLERGIES, ALZHEIMER'S DISEASE, ASTHMA, AUTOIMMUNE DISEASES AND DISORDERS, CANCER, CARDIOVASCULAR DISEASES AND DISORDERS, NEUROLOGICAL AND CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS, ENDOCRINE DISEASES AND DISORDERS, ERECTILE DYSFUNCTION AND SEXUAL DISORDERS, GASTROINTESTINAL DISEASES AND DISORDERS, GYNECOLOGICAL AND FERTILITY DISEASES AND DISORDERS, HEMOLYTIC DISEASES AND DISORDERS, HORMONAL DISEASES AND DISORDERS, HYPERTENSION, INFECTIOUS DISEASES, IMMUNOLOGICAL DISEASES AND DISORDERS, BACTERIAL DISEASES AND DISORDERS, VIRAL DISEASES AND DISORDERS AND FUNGAL DISEASES AND DISORDERS, INFLAMMATION AND INFLAMMATORY DISEASES AND DISORDERS, METABOLIC DISEASES AND DISORDERS, MIGRAINES, MUSCULOSKELETAL DISEASES AND DISORDERS, NEOPLASTIC DISEASES AND DISORDERS, OBESITY, OPHTHALMOLOGICAL AND EYE DISEASES AND DISORDERS, OSTEOPOROSIS, PAIN, PARKINSON DISEASE, PSYCHIATRIC DISEASES AND DISORDERS, RESPIRATORY DISEASES AND DISORDERS, TOBACCO AND ADDICTIONS TO SUBSTANCES AND RELATED DISEASES DISORDERS, CEREBROVASCULAR ACCIDENTS, UROLOGICAL DISORDERS, WEIGHT CONTROL AND APPETITE.
www.wipo.int/branddb/en/showData.jsp?ID=MXTM.0119851932637
- Hmm.
- One pending MannKind-Mexican trademark that caught my attention was this one. The mark is AFRESA and was filed in March 2018.
Status: Pending (2018-03-12)
Serial number of the application
0119852021378
Date of filing of the application
2018-03-12
Reproduction of the mark where the mark is represented in standard characters
AFRESA
Indication relating to the nature or kind of mark
Trade mark
Name and address of the applicant
MANNKIND CORPORATION
RUSSELL RANCH ROAD NUM. EXT. 30930 NUM. INT. SUITE 301
WESTLAKE VILLAGE, CA., ESTADOS UNIDOS DE AMERICA (91362)
Name and address of the representative
ANTONIO BELAUNZARAN MARTINEZ
PEDRO LUIS OGAZON NUM. EXT. 17, SAN ANGEL
ALVARO OBREGON, CIUDAD DE MEXICO (01000)
The International Classification of Goods and Services for the Purposes of the Registration of Marks (Nice Classification) and the list of goods and services classified according thereto
PREPARACIONES FARMACEUTICAS.
…translating…
PHARMACEUTICAL PREPARATIONS.
www.wipo.int/branddb/en/showData.jsp?ID=MXTM.0119852021378
- List of the 17 active and 6 pending MannKind-Mexican trademarks.
